Declaration Partners — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Synthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems.
BiotechDeep TechHealthtechMedical DevicesRedwood City, US
Paul John Dabrowski(Executive Officer, Director)Michael Jakub Dabrowski(Executive Officer, Director)
BoardDrew Oetting(Director)inScott Nolan(Director)in
Co-investorsAAF Management Ltd.AME Cloud VenturesFounders FundKhosla VenturesMenlo VenturesOpen Field Capital+8 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.